pre-IPO PHARMA

COMPANY OVERVIEW

ARMGO Pharma, Inc., is a privately held biopharmaceutical company dedicated to applying targeted mechanism-based science to the development of novel small-molecule therapeutics to treat cardiac, musculoskeletal, and neurological disorders characterized by leaky Ryanodine Receptor (RyR) calcium channels. Leaky RyRs are caused by genetic mutations as well as post-translational modifications of RyR channels. The company's proprietary drugs, known as Rycals®, are a new class of oral agents that repair calcium leaks through the RyR. ARMGO Pharma has been awarded an exclusive, worldwide license from Columbia University for its RyR technology based on the research of founding scientist Andrew R. Marks, M.D. The ARM210 program is supported through a Bench to Bedside grant from the NIH (NNS19005001), and a research collaboration and financial support from Les Laboratoires Servier.


LOCATION

  • Tarrytown, NY, USA

  • THERAPEUTIC AREAS

  • Cardiovascular
  • Musculoskeletal Disease
  • Neurological Disorders

  • WEBSITE

    http://www.armgo.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    aisling-capital


    PRESS RELEASES


    Dec 17, 2019

    ARMGO Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies


    Sep 5, 2018

    ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies


    Dec 9, 2015

    ARMGO Pharma Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ARM210/S48168 for the Treatment of Duchenne Muscular Dystrophy


    Dec 4, 2014

    ARMGO Pharma and Servier Announce Advancement of Rycal ARM210/S48168 into Clinical Stage Program Targeting Duchenne Muscular Dystrophy


    Nov 6, 2013

    ARMGO Pharma Receives Research Grant Award from Kennedy's Disease Association to Support Advancement of Rycal Compounds


    For More Press Releases


    Google Analytics Alternative